Are you more interested in the of enVVeno or the hardware scalability of Enovix for your portfolio?
The company recently reported its full-year 2025 results, showing a net loss of $19.5 million. However, it maintains a cash position of $28.2 million , which is expected to support operations through the initiation of the enVVe pivotal trials in 2026. buy envv stock
With an expected quarterly cash burn of $4–$5 million , the company is in a race against its own runway to reach significant clinical milestones. Enovix Corporation (ENVX): The Battery Tech Contender Are you more interested in the of enVVeno
Wall Street is divided. While the consensus rating is a "Buy" with an average price target of $13.46 , some major firms like Bank of America and Wells Fargo have more cautious targets of $6.00 , citing manufacturing hurdles and long qualification cycles for smartphones. Summary Table: Quick Comparison (April 2026) enVVeno Medical (ENVV) Enovix (ENVX) Primary Focus Medical Devices (Venous Valves) Next-Gen Silicon-Anode Batteries Recent Price ~$5.10 (as of 4/27/26) ~$6.51 (as of 4/27/26) Outlook High-risk trial phase Scaling manufacturing in Malaysia Catalysts enVVe pivotal trial start Q1 Earnings on May 13, 2026 With an expected quarterly cash burn of $4–$5
The stock has recently seen speculative rallies based on rumored partnerships, including a potential battery supply deal with Meta for AR glasses.
Often searched as "ENVX," this company is a favorite among growth-oriented retail and institutional investors.